APP and Alzheimer disease: In the APP/PS1 AD mouse model, intraperitoneal administration of neutralizing anti-VEGF-A antibodies ameliorated capillary stalling, normalized BBB permeability, and increased cerebral blood flow (CBF) (capillary stalling and reduced CBF are associated with cognitive impairment in AD patients) (Ali et al., 2022).